shutterstock-188738180-web
360b / Shutterstock.com
16 July 2014Asia

Bayer loses another Nexavar compulsory licence appeal in India

The Mumbai High Court has upheld India-based Natco Pharma’s compulsory licence on Bayer’s kidney cancer drug Nexavar (sorafenib).

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Generics
23 November 2021   Bayer Healthcare and Amgen subsidiary Onyx Pharmaceuticals have dropped a patent infringement suit against Dr Reddy’s over a planned generic version of cancer treatment Nexavar.

More on this story

Generics
23 November 2021   Bayer Healthcare and Amgen subsidiary Onyx Pharmaceuticals have dropped a patent infringement suit against Dr Reddy’s over a planned generic version of cancer treatment Nexavar.

More on this story

Generics
23 November 2021   Bayer Healthcare and Amgen subsidiary Onyx Pharmaceuticals have dropped a patent infringement suit against Dr Reddy’s over a planned generic version of cancer treatment Nexavar.